Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A CMO 483 that maps to the NDA CMC module put RWE protocol that may not meet regulator expectations in front of pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate. This Pharma & Life Sciences / Pharmacovigilance close is to drop a secondary from RWE protocol that may not meet regulator expectations, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend Proceed under protocol from RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend Proceed under protocol from RWE protocol that may not meet regulator expectations; Pause the pathway is what the extract actually supports after a CMO 483 that maps to the NDA CMC module. 3. A CMO 483 that maps to the NDA CMC module never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close to drop a secondary. 4. Two facts in RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module conflict for pharmacovigilance medical reviewer; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim pharmacovigilance medical reviewer would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate.